Search
Lisuride
go.drugbank.com/drugs/DB00589ApprovedAn ergot derivative that acts as an agonist at dopamine D2 receptors (dopamine agonists). It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (serotonin agonists).
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor AgonistsRibosome-binding protein 1
go.drugbank.com/bio_entities/BE0003466TargetHumansActs as a ribosome receptor and mediates interaction between the ribosome and the endoplasmic reticulum membrane
Synonyms: Ribosome receptor protein, 180 kDa ribosome receptor homologNatural killer cells antigen CD94
go.drugbank.com/bio_entities/BE0010559TargetHumansImmune receptor involved in self-nonself discrimination.
Synonyms: NK cell receptor, Killer cell lectin-like receptor subfamily D member 1Function: HLA-A specific activating MHC class I receptor activityVusolimogene oderparepvec
go.drugbank.com/drugs/DB23008ApprovedInvestigational[L64061,L64062] It is the second oncolytic viral therapy approved in the United States, following talimogene laherparepvec (T-VEC, Imlygic) in 2015, and the first approved for melanoma that has progressed … [L64062,L64063] The approval came on the therapy's third submission, after two prior complete response letters.[L64063]
V-type immunoglobulin domain-containing suppressor of T-cell activation
go.drugbank.com/bio_entities/BE0010797TargetHumansImmunoregulatory receptor which inhibits the T-cell response (PubMed:24691993). May promote differentiation of embryonic stem cells, by inhibiting BMP4 signaling (By similarity).
Synonyms: Platelet receptor Gi24, V-set immunoregulatory receptorLinvoseltamab
go.drugbank.com/drugs/DB17447ApprovedInvestigationalcells with CD3-expressing T cells. … By binding to both targets simultaneously, linvoseltamab redirects T cells toward myeloma cells, forming an immunological synapse that activates T-cell–mediated cytotoxicity.
Categories: Bispecific B Cell Maturation Antigen-directed CD3 T Cell EngagerSynonyms: human IgG4-based anti-CD3 x anti-BCMA bispecific monoclonal antibody that binds to CD3 and BCMAMethapyrilene
go.drugbank.com/drugs/DB04819ApprovedWithdrawnMethapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979.
Tucatinib
go.drugbank.com/drugs/DB11652ApprovedInvestigationalIt was developed by Seattle Genetics and approved by the FDA on April 17, 2020. … Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer.
Categories: Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitorsLoncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigationalZylonta also received approval in the EU on December 22, 2022. … [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.
Synonyms: Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through A protease cleavable valine-alanine linker